REDWOOD CITY, Calif., July 30, 2025 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx” or the "Company"), a global leader in minimally invasive treatments for lung disease, today reported financial results for the second quarter of 2025 ended June 30, 2025. Recent Highlights Achieved worldwide revenue of $23.9 million in the second quarter of 2025, a 15$9.1 million in international revenue ...